Yang Shuan-ying, Xiao Xue-yuan, Zhang Wang-gang, Sun Xiu-zhen, Zhang Li-juan, Zhang Wei, Zhou Bin, Yang De-chang, He Da-cheng
Department of Respiratory Medicine, Second Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2006 Jan;29(1):31-4.
To explore the application of serum surface-enhanced laser desorption/ionization (SELDI) marker patterns in distinguishing non-small cell lung cancer patients from healthy people by protein chip technology.
One hundred and sixty-three serum samples (123 patients with lung cancer and 40 healthy persons), were randomly divided into a training set [94 cases, 53 non-small cell lung cancer (NSCLC), 21 small cell lung cancer and 20 healthy persons] and a blinded test set (69 cases), were included for analysis by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Five protein peaks at 11,493, 6,429, 8,245, 5,336 and 2,536 were automatically chosen for the system training and the development of a decision classification tree model (marker pattern). The accuracy of the model was tested with the blinded test set (an independent set of masked serum samples from 49 patients with NSCLC and 20 healthy persons).
The model differentiated the patients with NSCLC from the healthy people with a sensitivity of 95.9% (71/74) and a specificity of 90.0% (18/20) in the training set and a sensitivity of 83.7%, and a specificity of 80.0% in the blinded set respectively.
SELDI-TOF-MS technique can correctly distinguish NSCLC patients from healthy people, and it has the potential for the development of a screening test for the detection of NSCLC.
通过蛋白质芯片技术探索血清表面增强激光解吸/电离(SELDI)标志物模式在区分非小细胞肺癌患者与健康人方面的应用。
163份血清样本(123例肺癌患者和40例健康人)被随机分为训练集[94例,其中53例非小细胞肺癌(NSCLC)、21例小细胞肺癌和20例健康人]和盲法测试集(69例),采用表面增强激光解吸/电离飞行时间质谱(SELDI-TOF-MS)进行分析。系统自动选择11493、6429、8245、5336和2536处的5个蛋白峰进行训练,并建立决策分类树模型(标志物模式)。用盲法测试集(来自49例NSCLC患者和20例健康人的一组独立的血清样本)对模型的准确性进行测试。
在训练集中,该模型区分NSCLC患者与健康人的灵敏度为95.9%(71/74),特异度为90.0%(18/20);在盲法测试集中,灵敏度为83.7%,特异度为80.0%。
SELDI-TOF-MS技术能够正确区分NSCLC患者与健康人,具有开发NSCLC筛查检测方法的潜力。